Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Anesthesiology & Pain Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Emergency Medicine Urology Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Substance-Related Disorders

Subtypes of Substance-Related Disorders

Substance Use Disorder 30 Drug use disorders 1

34 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Substance-Related Disorders

55 trials tracked for Substance-Related Disorders: 9 in phase 3 or 4 and 4 with published results. The most-cited published study has 80 citations.

55Trials tracked

9Phase 3 & 4

0Recruiting

4With published results

Phase distribution

Phase 4 4 Phase 3 5 Phase 2 3 Phase 1 5 Other / NA 38

Phase 4 Relapse Prevention With Varenicline Completed · 80 cited
Phase 4 Smoking Cessation Treatment for Methadone Maintenance Patients Completed · 80 cited
Phase 3 Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders Completed · 28 cited
Phase 4 Buprenorphine to Improve HIV Care Engagement and Outcomes Completed · 22 cited
Phase 4 Interactions Between Drug Effects and Environments II Completed
Phase 3 Rapid HIV Testing and Counseling in Drug Abuse Treatment Completed

Show 44 more trials

Phase 3 Treating Violence-Prone Substance Use Disorder Patients Completed
Phase 3 Prescription Opioid Addiction Treatment Study (POATS) Completed
Phase 3 Voucher-Based Incentives in a Prevention Setting Completed
Phase 2 Combined Treatment for Alcohol-Dependent Individuals With PTSD Completed
Phase 2 Prescription Opioid Effects in Abusers Versus Non-Abusers Completed
Phase 2 Interactive Motivational Media for Perinatal Drug Abuse - 3 Completed
Phase 1 Pilot Clinical Trial of Computer-based Motivational Intervention - 1 Completed
Phase 1 Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults Completed
Phase 1 The Women's Recovery Group Study: Stage I Trial Completed
Phase 1 Alcohol, Behavior, and Brain Imaging Completed
Phase 1 Middle School to High School Transition Project: Depression and Substance Abuse Prevention Completed
N/A MISSION-Vet HUD-VASH Implementation Study Completed
N/A Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation Completed
N/A Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace Completed
N/A We The Village Family Support Study Completed
N/A A Brief Community Linkage Intervention for Dually Diagnosed Individuals Completed
N/A Community Health Worker Training to Reduce Depression and Substance Use Stigma in TB/HIV Care in South Africa Completed
N/A Mindfulness Meditation for the Treatment of Women With Comorbid PTSD and SUD Completed
N/A Women's Treatment and Early Recovery Completed
N/A Treatment Engagement With Technology-assisted Treatment Completed
N/A Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services Completed
N/A Preventing Impaired Driving Among Adolescents Completed
N/A Screening to Augment Referral to Treatment- Project START Completed
N/A Incentives to Decrease Opioid Use - Pilot Completed
N/A A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Completed
N/A Intervention for Veterans With Depression, Substance Disorder, and Trauma Completed
N/A Preventing Addiction Related Suicide (PARS) Completed
N/A Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3 Completed
N/A Preventing Violence Among Veterans in Substance Use Disorder Treatment Completed
N/A Testing a Brief Substance Misuse Preventative Intervention for Parents/Guardians of 5th-7th Grade Students Completed
N/A A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot Completed
N/A SET-Recovery/Healthy Home Completed
N/A Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal Completed
N/A Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers Completed
N/A Encouraging Judicious Prescribing of Opioids in Los Angeles County Completed
N/A Behavioral Insights to Encourage Judicious Prescribing of Opioids Completed
N/A Development of a Patient Centered Mental Health Intervention for Recent Veterans Completed
N/A First Episode Schizophrenia and Cannabis-Related Disorder Study Completed
N/A Multisite RCT of STEP-Home: A Transdiagnostic Skill-based Community Reintegration Workshop Completed
N/A Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1 Completed
N/A Screening and Brief Advice to Reduce Teen Substance Use Completed
N/A Optimizing Behavioral Health Homes for Adults With Serious Mental Illness Completed
N/A Scalable Digital Delivery of Evidence-based Training for Professionals to Maximize Treatment Rates of OUD in Families Completed
N/A Data-driven Identification for Substance Misuse Completed

Showing the 50 most-cited and recently-updated of 55 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Substance-Related Disorders: what the trials found

Varenicline was evaluated for smoking cessation; results showed no significant difference in biochemically verified abstinence (p=0.24) or severe global psychiatric symptoms (p=0.15) ³. Clinical data noted a mean of 9.1 to 37 days for attempts to quit lasting at least 24 hours ³, with reported times to relapse of 9.1 and 16.4 days ⁴.

Behavioral and pharmacological interventions include Buprenorphine/naloxone ⁵, stimulant or sedative administration ⁶, and Oxygen (15-O) Water ⁷. Other established protocols include Interpersonal Violence Prevention Intervention ⁹, Voucher-Based Reinforcement Therapy ¹⁰, Standard Medical Management of Prescription Opiate Abuse ¹¹, and Brief computer-delivered interventions [14, 19].

Public health interventions for high-risk behaviors included on-site HIV rapid testing and brief counseling; this resulted in significantly higher rates of self-reported receipt of results (p<0.001) and a significant reduction in the sharing of needles used in drug use (p=0.044) ⁸.

Recent results — preliminary, needs further review

Mindfulness Meditation was associated with significantly higher treatment completion rates, fewer days of any drug use, and lower scores for psychological symptoms (all p<0.05) ².
webCHAT showed no significant differences in outcomes related to alcohol/cannabis use, driving under the influence, or riding with an impaired driver ¹.
Processing clinical notes in EHR data during routine care showed no significant difference in the proportion of patients with a universal screen positive who received SBIRT (p=0.20) ²⁰.
Other recent interventions include commercially available cigarettes ²¹ and the Preventing Addiction Related Suicide (PARS) program ²².

For the clinician treating this condition

Mindfulness Meditation is associated with improved treatment completion and reduced drug use days compared to standard approaches.
Varenicline shows no significant impact on biochemical abstinence or psychiatric symptom severity in the studied populations.
On-site rapid testing combined with brief counseling significantly reduces needle-sharing behaviors among drug users.

AI synthesis of 14 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

‹ Prev 1 2 3 Next ›